. 2021 Aug;21(5):938-941.

doi: 10.1016/j.pan.2021.03.015. Epub 2021 Mar 28.

Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer

Affiliations

¹ Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA.
⁴ Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
⁵ Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁶ Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁷ Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: aklein1@jhmi.edu.
⁸ Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: nrobert8@jhmi.edu.

PMID: 33839031
PMCID: PMC8355034
DOI: 10.1016/j.pan.2021.03.015

Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer

Cancan Zhou et al. Pancreatology. 2021 Aug.

. 2021 Aug;21(5):938-941.

doi: 10.1016/j.pan.2021.03.015. Epub 2021 Mar 28.

Authors

Affiliations

¹ Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA.
⁴ Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
⁵ Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁶ Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁷ Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: aklein1@jhmi.edu.
⁸ Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: nrobert8@jhmi.edu.

PMID: 33839031
PMCID: PMC8355034
DOI: 10.1016/j.pan.2021.03.015

Abstract

Background: Pancreatic cancer is a lethal disease with a poor 5-year survival rate. Pathogenic germline variants in the coding regions of ATM, BRCA1, and BRCA2 are found in up to 4.8% of pancreatic cancer patients. Germline promoter methylation and gene silencing arising from a germline variant or through other mechanisms have been described as a cause of tumor suppressor gene inactivation.

Methods: We measured the level of promoter methylation of the ATM, BRCA1, and BRCA2 genes in peripheral blood lymphocytes from 655 patients with pancreatic cancer using real-time PCR.

Results: No evidence of germline promoter methylation of any of these genes was found. Promoter methylation levels were minimal with no patient having promoter methylation greater than 3.4%, 3.3%, and 7.6% for ATM, BRCA1 and BRCA2, respectively, well below levels found in patients who have inherited promoter methylation (∼50%).

Conclusions: We found no evidence of germline promoter methylation for the pancreatic susceptibility genes ATM, BRCA1 and BRCA2 in patients with pancreatic cancer. This study reveals that constitutive germline methylation of promoter CpG islands is rare in pancreatic cancer.

Keywords: Cancer; CpG island; Inherited; Methylation; Pancreas.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest R.H.H has the right to receive royalty payments from Thrive Earlier Diagnosis for the GNAS in pancreatic cysts invention. The authors declare no other conflicts of interest.

Figures

**Figure 1.. Methylation of *ATM*, *BRCA1* and *BRCA2* promoter CpG islands in patients with pancreatic cancer.**
Percent methylation of *ATM*, *BRCA1* and *BRCA2* promoter CpG islands for 655 patients with pancreatic cancer. No patient had promoter methylation greater than 3.4%, 3.3%, and 7.6% respectively, indicating that no patient had inherited variants that promote constitutive methylation of these regions.

See this image and copyright information in PMC

References

1. Viale PH: The american cancer society’s facts & figures: 2020 edition. J Adv Pract Oncol 2020; 11: 135–136. - PMC - PubMed
1. Chen F, Roberts NJ, Klein AP: Inherited pancreatic cancer. Chin Clin Oncol 2017; 6: 58. - PMC - PubMed
1. Thompson ED, Roberts NJ, Wood LD, Eshleman JR, Goggins MG, Kern SE et al.: The genetics of ductal adenocarcinoma of the pancreas in the year 2020: Dramatic progress, but far to go. Mod Pathol 2020; 33: 2544–2563. - PMC - PubMed
1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30. - PubMed
1. Stoffel EM, McKernin SE, Khorana AA: Evaluating susceptibility to pancreatic cancer: Asco clinical practice provisional clinical opinion summary. J Oncol Pract 2019; 15: 108–111. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

P50 CA062924/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer

Affiliations

Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous